Let's have our traditional Reading of Tea Leaves b
Post# of 153937
(Total Views: 534)
Posted On: 12/30/2020 12:58:39 PM
Let's have our traditional Reading of Tea Leaves before every CC announcement. Please comment/advise/admonish/cheerlead as desired.
1. No mention of Philippines EUA - Because it would have been a done deal prior to the CC and thus we will have a PR beforehand? OR Cytodyn no longer deems worthwhile to pursue before CD12 readout? I expect this will be addressed during Q&A.
2. BLA's are at the top of the list - Does this mean we will finally get some good news or more concrete timelines?
3. Why only mention about potential revenues/manufacturing for HIV and not Covid? Does this mean that it's a foregone conclusion that current supplies (and revenue) for Covid are already spoken for ala OWS?
4. Nasdaq uplisting is specifically listed for discussion - Past few CC's tended to shy away from this topic and management was ill prepared to discuss when brought up in Q&A's. I think with share price being above $4 and NP mentioning investors would be "happy to see Q or K at end of November", Cytodyn must have some good news to share on imminent uplisting possibility. Or perhaps that optimism may be just what we all knew all along, that uplisting is an inevitability with positive CD12 results anyway. My preference if at all possible would be to uplist prior to EUA which will maximize the take off (of the
1. No mention of Philippines EUA - Because it would have been a done deal prior to the CC and thus we will have a PR beforehand? OR Cytodyn no longer deems worthwhile to pursue before CD12 readout? I expect this will be addressed during Q&A.
2. BLA's are at the top of the list - Does this mean we will finally get some good news or more concrete timelines?
3. Why only mention about potential revenues/manufacturing for HIV and not Covid? Does this mean that it's a foregone conclusion that current supplies (and revenue) for Covid are already spoken for ala OWS?
4. Nasdaq uplisting is specifically listed for discussion - Past few CC's tended to shy away from this topic and management was ill prepared to discuss when brought up in Q&A's. I think with share price being above $4 and NP mentioning investors would be "happy to see Q or K at end of November", Cytodyn must have some good news to share on imminent uplisting possibility. Or perhaps that optimism may be just what we all knew all along, that uplisting is an inevitability with positive CD12 results anyway. My preference if at all possible would be to uplist prior to EUA which will maximize the take off (of the
(3)
(0)